Motilent is a technology SME pioneering innovative services for quantitative investigation of the gut. Utilizing novel MRI post-processing software as a cost-effective and safer biomarker for Gastrointestinal and Bowel Disorders, Motilent provides quantitative endpoints for research, drug development, and clinical decision-making. The company's slogan, "Changing the way we see the gut," captures its mission to revolutionize the perception and treatment of gastrointestinal health. As of now, details on the founded date, industries, headquarters, last investment, and last investment investors are not publicly available. However, with an offering poised at the intersection of healthcare and technology, Motilent presents an intriguing opportunity for investors seeking to tap into the burgeoning field of digital health and medical technology.
Motilent
Changing the way we see the gut
London, United Kingdom
22 employees
Get notified when Motilent moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Motilent
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
United Kingdom Market
About Motilent
Taxonomy: MRI post-processing software, Gastrointestinal disorders, Bowel disorders, Quantitative investigation, Biomarker, Research, Drug development, Clinical decision-making
No funding data available for Motilent yet.
Get notified when Motilent raises fundingMotilent Alternatives & Competitors
Pioneering precision neuroscience to restore cognitive and motor function through groundbreaking med...
A psychology practice that treats ADHD, ODD, and other learning and behavioral disorders
Discover Your Next Breakthrough
FAQ About Motilent
Don't just browse. Track.
Signal Tracker monitors Motilent and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.